What Samay does:

Samay leverages AI and wearables to revolutionize remote respiratory health monitoring. The company’s flagship product, Sylvee, is a groundbreaking, non-invasive lung function monitoring device. It combines innovative, patented hardware with a proprietary machine learning system to detect COPD, asthma, exacerbation biomarkers, and medication response.

By empowering patients and physicians with real-time insights, Samay’s Sylvee aims to improve early diagnosis, enhance clinical management, and accelerate the development of effective therapeutics. With over 1billion people worldwide affected by respiratory issues and less than half receiving proper diagnosis and care, respiratory diseases pose a significant global health burden, costing over $8 trillion annually.

Maria Artunduaga, Founder and CEO of Samay, shared this testimonial:

The ATS Respiratory Innovation Summit has been a pivotal catalyst for our growth. Our 2023 podium presentation connected us with a network of influential industry leaders, including 200+ investors, physicians, founders, and executives. This exposure has enabled us to secure a crucial partnership with a Fortune 500 company, raise an additional $1.5M of funding, and leverage the expertise of pulmonary experts from ATS's vast network to improve our clinical studies. These advancements have significantly propelled our go-to-market strategy and business model development.

Learn more about Samay and its flagship groundbreaking product, Sylvee.